Did Tobacco Trade Ads for Votes?

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 10
Volume 7
Issue 10

WASHINGTON--The US Department of Justice is reviewing a complaint by the Campaign for Tobacco-Free Kids that the big tobacco companies may have violated election laws by promising to run TV ads that would give senators "political cover" on the tobacco issue if they voted against the McCain tobacco control bill, which was defeated last June.

WASHINGTON--The US Department of Justice is reviewing a complaint by the Campaign for Tobacco-Free Kids that the big tobacco companies may have violated election laws by promising to run TV ads that would give senators "political cover" on the tobacco issue if they voted against the McCain tobacco control bill, which was defeated last June.

The tobacco companies say that they have not funded any ads for candidates and that their ads are not political but rather advocacy ads that review the possible negative ramifications of tobacco control measures such as the McCain bill.

Articles in this issue
Panel Recommends Photofrin for Use in Late-Stage Lung Cancer
California Intervention Raises Consumption of Fruits and Vegetables
ODAC Panel Okays Nolvadex to Reduce Breast Cancer Risk
Evolving Role for Preoperative Chemo in Breast Cancer
NCI Sets Sail on a New Tack In the Stormy Seas of CAM
Opioid Antagonists Can Control Opioid-Induced Constipation
NCI Seeks New Technologies
View Cancer Pain as a ‘Pathogenic Agent’ to be Treated, Expert Says
NIAID Collaborates With VaxGen, Inc. on Trials of AIDSVAX
Clinicians Often Fail To Provide Adequate Genetic Counseling
Networks Assist Community Oncologists in Research Quest
Three Months After Voting Nay, ODAC Backs Valstar Approval
M.D. Anderson Center Will Consolidate Faculty Offices in New Building in 2000
Drug-Seeking Behavior in Pain Patients Rarely Addiction
Device Finds Breast Lesions by Measuring Electropotentials

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
A study aimed to determine the variables that correlated with extravasation rates in patients receiving radiation injection therapy.
Related Content
Univariate and multivariate analyses showed no significant association between statin use and grade 3 or higher toxicities in patients with CLL or SLL.

Concurrent Statin Use With Treatment Improves Survival in CLL/SLL

Roman Fabbricatore
April 25th 2025
Article

Univariate and multivariate analyses showed no significant association between statin use and grade 3 or higher toxicities in patients with CLL or SLL.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

CHMP Recommends Brentuximab Vedotin/Chemo in Advanced Hodgkin Lymphoma

CHMP Recommends Brentuximab Vedotin/Chemo in Advanced Hodgkin Lymphoma

Tim Cortese
April 25th 2025
Article

Results from the phase 3 HD21 trial showed that brentuximab vedotin plus chemotherapy was superior to alternative treatments in Hodgkin lymphoma.

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Roman Fabbricatore
April 25th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

"...The reported feasibility and activity of this combination warrant further evaluation in switch maintenance in the metastatic setting or consolidation after definite chemoradiation for patients with limited-stage SCLC," according to the study authors.

Lurbinectedin/Pembrolizumab Shows Significant Activity in Relapsed SCLC

Russ Conroy
April 25th 2025
Article

Findings from the phase 1/2 LUPER trial support further assessment of lurbinectedin plus pembrolizumab in relapsed small cell lung cancer.